Aleix Prat, MD, PhD, of Hospital Clinic de Barcelona, discusses the findings of a meta-analysis showing that the HER2-E subtype may predict pathologic complete response beyond hormone receptor status in HER2-positive early breast cancer (Abstract 248P).
Antonio González Martín, MD, PhD, of the Clínica Universidad de Navarra, discusses study findings showing niraparib therapy significantly improved progression-free survival in patients with advanced ovarian cancer across biomarker subgroups (Abstract LBA1).
Nicholas D. James, PhD, MBBS, of University Hospitals Birmingham NHS Trust, discusses the efficacy of prostate radiotherapy plus androgen-deprivation therapy with or without docetaxel in patients with prostate cancer with only lymph node metastases or less than four bone metastases (Abstract 844O).
Thomas Powles, MD, PhD, of Queen Mary University of London, discusses the first study to examine immunotherapy and targeted treatment combinations with a personalized approach in bladder cancer. FGF, TORC1/2, and PARP inhibitors were explored in combination with durvalumab in selected patients (Abstract 902O).
Maha H.A. Hussain, MD, of Northwestern University Robert H. Lurie Comprehensive Cancer Center, discusses the phase III PROfound trial results on the efficacy of olaparib in men with metastatic castration-resistant prostate cancer whose tumors harbor alterations in DNA damage response genes and who had disease progression on prior hormone therapy (Abstract LBA12).
Solange Peters, MD, PhD, of the Oncology Department of CHUV, discusses study findings from the first phase III trial to show PD-1 and CTLA-4 inhibition is effective in non–small cell lung cancer, with improved overall survival vs chemotherapy (Abstract LBA4).
